Most lately, it has been identified that conolidine and the above derivatives act over the atypical chemokine receptor 3 (ACKR3. Expressed in very similar spots as classical opioid receptors, it binds to some wide array of endogenous opioids. Not like most opioid receptors, this receptor acts like a scavenger and would not activate a next messenger